Filing Flows › Medifast (MED) › Q2 2026 › vs Q1 2026
Medifast (MED) Q2 2026 vs Q1 2026 (quarter over quarter)
Medifast's revenue rose $340K (+0.4%) from $76.0M in Q1 2026 to $76.4M in Q2 2026.
Medifast, Q2 2026: revenue $76.4M (-28% year over year), operating margin -5.7%, net loss $3.1M, operating cash flow $1.7M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 1.0% | -1.1% | +2.1 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $76.4M | $76.0M | $340K | +0.4% |
| Other income, net | $1.3M | $1.4M | −$18K | -1% |
| Net loss | $3.1M | $2.1M | $978K | +46% |
| Costs & expenses | $80.8M | $79.5M | $1.3M | +2% |
| Operating costs | $80.7M | $79.3M | $1.4M | +2% |
| Income tax | $109K | $181K | −$72K | -40% |
| Cost of revenue | $23.0M | $24.3M | −$1.3M | -5% |
| Operating expenses | $57.7M | $55.1M | $2.7M | +5% |
| Operating cash sources | $5.3M | $5.4M | −$115K | -2% |
| Depreciation & amortization | $3.4M | $3.5M | −$37K | -1% |
| Share-based compensation | $1.8M | $1.9M | −$78K | -4% |
| Net loss absorbed | $3.1M | $2.1M | $978K | +46% |
| Working capital & other | $467K | $3.0M | −$2.5M | -84% |
| Operating cash flow | $1.7M | $260K | $1.4M | +553% |
| Free cash flow (OCF − capex) | $728K | −$836K | $1.6M | — |
| Capital expenditures | $969K | $1.1M | −$127K | -12% |
Questions
How much did Medifast's revenue grow quarter over quarter in Q2 2026?
Medifast's revenue rose $340K (+0.4%) from $76.0M in Q1 2026 to $76.4M in Q2 2026.